CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis

NASDAQ:CPRX • US14888U1016

23.88 USD
0 (0%)
Last: Mar 3, 2026, 03:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

CPRX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on CPRX. These ratings could make CPRX a good candidate for value and quality investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year CPRX was profitable.
  • CPRX had a positive operating cash flow in the past year.
  • Of the past 5 years CPRX 4 years were profitable.
  • Of the past 5 years CPRX 4 years had a positive operating cash flow.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 20.69%, CPRX belongs to the top of the industry, outperforming 96.73% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 23.65%, CPRX belongs to the top of the industry, outperforming 96.15% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 21.23%, CPRX belongs to the best of the industry, outperforming 97.88% of the companies in the same industry.
  • CPRX had an Average Return On Invested Capital over the past 3 years of 20.37%. This is in line with the industry average of 18.99%.
  • The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.69%
ROE 23.65%
ROIC 21.23%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

  • CPRX's Profit Margin of 37.64% is amongst the best of the industry. CPRX outperforms 97.12% of its industry peers.
  • CPRX's Profit Margin has been stable in the last couple of years.
  • Looking at the Operating Margin, with a value of 44.78%, CPRX belongs to the top of the industry, outperforming 99.23% of the companies in the same industry.
  • CPRX's Operating Margin has improved in the last couple of years.
  • The Gross Margin of CPRX (85.68%) is better than 88.08% of its industry peers.
  • In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
Industry RankSector Rank
OM 44.78%
PM (TTM) 37.64%
GM 85.68%
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 16.10 indicates that CPRX is not in any danger for bankruptcy at the moment.
  • CPRX has a Altman-Z score of 16.10. This is amongst the best in the industry. CPRX outperforms 87.31% of its industry peers.
  • There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 16.1
ROIC/WACC2.47
WACC8.61%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 6.62 indicates that CPRX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.62, CPRX is doing good in the industry, outperforming 66.92% of the companies in the same industry.
  • CPRX has a Quick Ratio of 6.40. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
  • CPRX has a Quick ratio of 6.40. This is in the better half of the industry: CPRX outperforms 65.38% of its industry peers.
Industry RankSector Rank
Current Ratio 6.62
Quick Ratio 6.4
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • CPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.01%, which is quite impressive.
  • The Earnings Per Share has been growing by 32.75% on average over the past years. This is a very strong growth
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.61%

3.2 Future

  • CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.46% yearly.
  • CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.11% yearly.
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue Next Year7.82%
Revenue Next 2Y8.79%
Revenue Next 3Y8.45%
Revenue Next 5Y9.11%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 14.13, which indicates a correct valuation of CPRX.
  • CPRX's Price/Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 95.96% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.13, CPRX is valued a bit cheaper.
  • A Price/Forward Earnings ratio of 12.36 indicates a correct valuation of CPRX.
  • Based on the Price/Forward Earnings ratio, CPRX is valued cheaply inside the industry as 97.12% of the companies are valued more expensively.
  • CPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.11.
Industry RankSector Rank
PE 14.13
Fwd PE 12.36
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • CPRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CPRX is cheaper than 98.08% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CPRX is valued cheaper than 97.50% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.43
EV/EBITDA 7.5
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.99
PEG (5Y)0.43
EPS Next 2Y13.06%
EPS Next 3Y6.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (3/3/2026, 3:05:23 PM)

23.88

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners86.97%
Inst Owner Change-0.4%
Ins Owners5.48%
Ins Owner Change1.13%
Market Cap2.92B
Revenue(TTM)N/A
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (47.36%)
Short Float %8.4%
Short Ratio7.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)16.56%
EPS beat(12)10
Avg EPS beat(12)13.3%
EPS beat(16)12
Avg EPS beat(16)8.79%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)0.21%
PT rev (3m)0%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)15.86%
EPS NY rev (1m)0.19%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.91%
Valuation
Industry RankSector Rank
PE 14.13
Fwd PE 12.36
P/S 5.04
P/FCF 12.43
P/OCF 12.42
P/B 3.17
P/tB 3.68
EV/EBITDA 7.5
EPS(TTM)1.69
EY7.08%
EPS(NY)1.93
Fwd EY8.09%
FCF(TTM)1.92
FCFY8.05%
OCF(TTM)1.92
OCFY8.05%
SpS4.73
BVpS7.54
TBVpS6.48
PEG (NY)0.99
PEG (5Y)0.43
Graham Number16.93
Profitability
Industry RankSector Rank
ROA 20.69%
ROE 23.65%
ROCE 28.06%
ROIC 21.23%
ROICexc 84.1%
ROICexgc 187.79%
OM 44.78%
PM (TTM) 37.64%
GM 85.68%
FCFM 40.59%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.31%
Cap/Sales 0.02%
Interest Coverage 593.88
Cash Conversion 79.12%
Profit Quality 107.83%
Current Ratio 6.62
Quick Ratio 6.4
Altman-Z 16.1
F-Score6
WACC8.61%
ROIC/WACC2.47
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.61%
Revenue Next Year7.82%
Revenue Next 2Y8.79%
Revenue Next 3Y8.45%
Revenue Next 5Y9.11%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%

CATALYST PHARMACEUTICALS INC / CPRX FAQ

What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to CPRX.


What is the valuation status for CPRX stock?

ChartMill assigns a valuation rating of 7 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.


Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?

CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 8 / 10.


What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?

The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 14.31% in the next year.